In the multibillion-dollar market for diabetes technology, Medtronic’s U.S. diabetes sales have declined in the last four years as the company grappled with regulators and competitors rolled out new devices.
With two strokes of a pen in late April, the Food and Drug Administration has given Medtronic a chance to change that. A warning letter over quality issues at its Northridge, Calif., diabetes device facility was lifted after two years, and the agency has approved Medtronic’s newest insulin pump, the MiniMed 780G, with its Guardian 4 sensor.
